Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

SOHO 2024 | Personalized treatments to manage post-transplantation outcomes in AML: insights from MORPHO

Name: Personalized treatments to manage post-transplantation outcomes in AML: insights from MORPHO
Uploaded: 2024-09-05T00:00:00Z
Duration: 1 min 46 s

Charles Craddock • 5 Sep 2024

SOHO 2024

Acute Myeloid Leukemia Leukemia Azacitidine Gilteritinib

AMADEUS MORPHO

Charles Craddock, CBE, FRCP, FRCPath, University of Birmingham, Birmingham, UK, discusses the MORPHO trial (NCT02997202), where gilteritinib showed benefits in a measurable residual disease (MRD)-positive subgroup of patients with FLT3-mutated acute myeloid leukemia (AML) post-transplantation. Prof. Craddock highlights the need for further exploration of targeted maintenance therapies, including menin and IDH inhibitors. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.